{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:35Z","timestamp":1792834715926,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sandoz, Inc."}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Adalimumab (ADA)-adaz (Hyrimoz\u00ae; Sandoz, Inc.) became available in the United States (US) in July 2023. This study assessed real-world ADA-adaz adoption experience by describing characteristics and treatment history of patients initiating ADA-adaz in the months following its US availability and preliminarily assessing persistence and adherence to ADA-adaz. A retrospective cohort study using open and closed claims from Komodo Research Data (01\/2016-05\/2024) was conducted. The index date was the first ADA-adaz prescription after July 2023. For the demographics and clinical assessment subgroup, \u226512 months of continuous data availability pre-index (baseline period) was required. For the persistence and adherence assessment subgroup, \u22653 months of continuous health plan enrollment post-index (study period) was required. Persistence was measured as time from index to the earlier of switch or discontinuation (45-day gap). Adherence was measured as the proportion of days covered (PDC) while on ADA-adaz. A total of 23,737 patients with an ADA-adaz prescription after July 2023 were included. For patients in the demographics and clinical assessment subgroup, the median age was 49.0 years, 59.4% were female, and 91.0% had commercial insurance. Patients received ADA-adaz mostly for rheumatoid arthritis (33.0%) and Crohn disease (23.2%). Common baseline comorbidities included hyperlipidemia (29.2%), hypertension (29.0%), anxiety (22.8%), and osteoarthritis (21.4%). During baseline, 93.2% of patients received a biologic; 98.2% received the reference ADA, and 83.0% were treated with biologics for at least 6 to 12 months. Other baseline treatments included systemic corticosteroids (52.3%), non-steroidal anti-inflammatory drugs (35.4%), and disease-modifying antirheumatic drugs (34.6%). Of the 1108 (4.7%) patients in the persistence and adherence assessment subgroup, persistence at 3 months was 65.7%, and average PDC was 93.9% while on ADA-adaz. These findings should be interpreted with caution due to limited follow-up availability. In summary, patients who initiated ADA-adaz in the months following its US availability were predominantly commercially insured. The high rate of prior ADA use highlighted a transition to biosimilars in biologic-experienced patients. The end of ADA-adaz persistence was largely driven by switching to other ADA treatments. Among patients with available short-term follow-up, adherence while on ADA-adaz was high. Further studies with longer follow-up can assess ADA-adaz utilization patterns and long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050452","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:25Z","timestamp":1787968825000},"page":"e50452","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early real-world utilization of ADA-adaz (Hyrimoz) in the United States"],"prefix":"10.1097","volume":"105","author":[{"given":"Anna","family":"Chen","sequence":"first","affiliation":[{"name":"Formerly at Sandoz Inc., Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7235-3292","authenticated-orcid":false,"given":"Rebecca","family":"Bungay","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Bedard","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Gobeil","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Li","sequence":"additional","affiliation":[{"name":"Sandoz Inc., Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"e243964","DOI":"10.1001\/jamahealthforum.2024.3964","article-title":"Use, spending, and prices of adalimumab following biosimilar competition.","volume":"5","author":"Rome","year":"2024","journal-title":"JAMA Health Forum"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajhp\/zxad086","article-title":"National trends in prescription drug expenditures and projections for 2023.","volume":"80","author":"Tichy","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2024.8917","article-title":"Formulary coverage of brand-name adalimumab and biosimilars across medicare part D plans.","volume":"332","author":"Klebanoff","year":"2024","journal-title":"JAMA"},{"key":"R4-20261024","first-page":"1226","article-title":"Budget impact analysis of including biosimilar adalimumab on formulary: a United States payer perspective.","volume":"30","author":"Chaplin","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jval.2020.12.020","article-title":"Factors associated with generic drug uptake in the United States, 2012 to 2017.","volume":"24","author":"Rome","year":"2021","journal-title":"Value Health"},{"key":"R6-20261024","first-page":"qxae090","article-title":"Biosimilar underutilization alone does not foretell a broken biologics market.","volume":"2","author":"LaMountain","year":"2024","journal-title":"Health Aff Sch"},{"key":"R7-20261024","first-page":"431","article-title":"Practical considerations for integrating biosimilars into clinical practice.","volume":"12","author":"May","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"e034183","DOI":"10.1136\/bmjopen-2019-034183","article-title":"Physicians\u2019 perceptions of the uptake of biosimilars: a systematic review.","volume":"10","author":"Sarnola","year":"2020","journal-title":"BMJ Open"},{"key":"R9-20261024","first-page":"102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review.","volume":"25","author":"Leonard","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","article-title":"Barriers and enablers affecting the uptake of biosimilar medicines viewed through the lens of actor network theory: a systematic review.","volume":"38","author":"Rieger","year":"2024","journal-title":"BioDrugs"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cpt.2765","article-title":"Prescriber perspectives on biosimilar adoption and potential role of clinical pharmacology: a workshop summary.","volume":"113","author":"Shubow","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"R12-20261024","first-page":"54","article-title":"Biosimilars: considerations for payers.","volume":"44","author":"Smeeding","year":"2019","journal-title":"P T"},{"key":"R14-20261024","first-page":"824","article-title":"Will the emerging private-label market access channel help or hinder biosimilar market access?","volume":"31","author":"Mehr","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"R16-20261024","article-title":"UnitedHealth to remove AbbVie\u2019s Humira from some US drug reimbursement lists next year.","author":"Wingrove","year":"2024","journal-title":"Reuters"},{"key":"R17-20261024","article-title":"Cigna to remove AbbVie\u2019s Humira from some drug reimbursement lists next year.","author":"Wingrove","year":"2024","journal-title":"Reuters"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A checklist for medication compliance and persistence studies using retrospective databases.","volume":"10","author":"Peterson","year":"2007","journal-title":"Value Health"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","article-title":"Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States.","volume":"8","author":"Bergman","year":"2021","journal-title":"Rheumatol Ther"},{"key":"R23-20261024","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.crohns.2011.05.005","article-title":"Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn\u2019s disease in the United States.","volume":"5","author":"Loftus","year":"2011","journal-title":"J Crohns Colitis"},{"key":"R24-20261024","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1080\/09546634.2021.1950600","article-title":"Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.","volume":"33","author":"Xu","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40744-017-0077-z","article-title":"Long-term effectiveness of adalimumab in patients with rheumatoid arthritis: an observational analysis from the corrona rheumatoid arthritis registry.","volume":"4","author":"Pappas","year":"2017","journal-title":"Rheumatol Ther"},{"key":"R27-20261024","first-page":"175","article-title":"Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy.","volume":"30","author":"Giavatto","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/rheumatology\/keaa502","article-title":"US rheumatologists\u2019 beliefs and knowledge about biosimilars: a survey.","volume":"60","author":"Gibofsky","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20261024","article-title":"Major US formulary change triggers, but does not sustain, increases in biosimilar adalimumab prescribing [published online ahead of print February 16, 2026].","author":"Roberts","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R31-20261024","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40259-018-0306-1","article-title":"Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent.","volume":"32","author":"Kristensen","year":"2018","journal-title":"BioDrugs"},{"key":"R32-20261024","first-page":"613","article-title":"Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.","volume":"41","author":"Scrivo","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R33-20261024","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1177\/2050640619883704","article-title":"Changes in inflammatory bowel disease patients\u2019 perspectives on biosimilars: a follow-up survey.","volume":"7","author":"Peyrin-Biroulet","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"R38-20261024","doi-asserted-by":"crossref","first-page":"e230117","DOI":"10.57264\/cer-2023-0117","article-title":"Navigating adalimumab biosimilars: an expert opinion.","volume":"12","author":"Abitbol","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"12 Suppl","key":"R39-20261024","first-page":"S227","article-title":"Provider and patient knowledge gaps on biosimilars: insights from surveys.","volume":"28","author":"Gibofsky","year":"2022","journal-title":"Am J Manag Care"},{"key":"R40-20261024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/87551225241306675","article-title":"Persistence after switching from adalimumab biosimilar MSB11022 to adalimumab biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases.","volume":"41","author":"Borras-Blasco","year":"2025","journal-title":"J Pharm Technol"},{"key":"R41-20261024","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/03007995.2023.2287600","article-title":"ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy.","volume":"39","author":"Santoleri","year":"2023","journal-title":"Curr Med Res Opin"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:00:16Z","timestamp":1792832416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050452"}},"subtitle":["A retrospective claims-based descriptive study"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":32,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050452","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2025-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}